Human cytomegalovirus neutralising antibodies and use thereof
AssigneeInstitute for Research in Biomedicine
InventorsAntonio LANZAVECCHIA, Annalisa MACAGNO
Life of this patent
Estimating the term…
Abstract
The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
Claims21
1-9. (canceled)
An isolated antibody, or an antigen binding fragment thereof, that is specific for a complex of human cytomegalovirus (hCMV) proteins UL130 and UL131A.
An isolated antibody, or an antigen binding fragment thereof, comprising the
- (a) CDR1, CDR2, and CDR3 sequences of the heavy and light chain variable region sequences set forth respectively in SEQ ID NOs:
- 7 and 8,
- (b) CDR1, CDR2, and CDR3 sequences of the heavy and light chain variable region sequences set forth respectively in SEQ ID NOs:
- 17 and 18, or
- (c) CDR1, CDR2, and CDR3 sequences of the heavy and light chain variable region sequences set forth respectively in SEQ ID NOs:
- 39 and 40.
An isolated antibody, or an antigen binding fragment thereof, comprising
- (a) heavy chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 1, 2, and 3, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 4, 5, and 6, respectively,
- (b) heavy chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 11, 12, and 13, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 14, 15, and 16, respectively, or
- (c) heavy chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 33, 34, and 35, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 36, 37, and 38, respectively.
An isolated antibody, or an antigen binding fragment thereof, comprising the
- (a) heavy and light chain variable region sequences set forth in SEQ ID NOs:
- 7 and 8, respectively, or sequences at least 85% identical thereto, or
- (b) heavy and light chain variable region sequences set forth in SEQ ID NOs:
- 17 and 18, respectively, or sequences at least 85% identical thereto, or
- (c) heavy and light chain variable region sequences set forth in SEQ ID NOs:
- 39 and 40, respectively, or sequences at least 85% identical thereto.
An isolated antibody, or an antigen binding fragment thereof, that binds to the same epitope as, or competes for binding with, an antibody comprising the
- (a) heavy and light chain variable region sequences set forth in SEQ ID NOs:
- 7 and 8, respectively,
- (b) heavy and light chain variable region sequences set forth in SEQ ID NOs:
- 17 and 18, respectively, or
- (c) heavy and light chain variable region sequences set forth in SEQ ID NOs:
- 39 and 40, respectively.
Dependencies are inferred from the claim text.